TRX BioSurgery Receives Supplier Horizon Award from Premier Inc.

One of 11 suppliers to receive the award this year, TRX BioSurgery was recognized for its support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs.

Joel Pickering, President, TRX BioSurgery, commented: “We are delighted to be recognized by Premier and its members for the Horizon award. As part of our regenerative medical device portfolio, DermaPure offers a novel treatment option to rebuild and repair diseased or worn out body parts, with compelling clinical outcomes and a strong health economic value proposition which was highlighted when we previously received approval under Premier’s ‘Breakthrough Technology Agreement’. We are excited to continue to build these relationships into the future.”

TRX BioSurgery accepted the award at Premier’s 2018 Breakthroughs Conference and Exhibition on June 19.

“TRX BioSurgery supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies,” said David A. Hargraves, Senior Vice President, Supply Chain, Premier. “We’re honored to recognize them as a Horizon Award recipient.”

Horizon Award winners have tenure of less than three years as a Premier contracted supplier.

About Premier Inc.

Premier Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and more than 150,000 other provider organizations. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Please visit Premier’s news and investor sites on www.premierinc.com.

About TRX BioSurgery

TRX BioSurgery is part of the Tissue Regenix Group, a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The Company’s patented decellularisation (‘dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012, Tissue Regenix Group plc set up a subsidiary company in the United States - ‘Tissue Regenix Wound Care Inc.’, January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight’s human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

www.tissueregenixus.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180620005567/en/